Garry Cooper
Affiliations: | Physiology and Chemistry | Northwestern University, Evanston, IL |
Area:
LTCC pharmacology in PDGoogle:
"Garry Cooper"Mean distance: 15.36 (cluster 6) | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentorD. James Surmeier | grad student | 2008-2014 | Northwestern | |
(Novel Selective Neuronal L-type Calcium Channel Inhibitors as Potential Therapeutics in Parkinson's Disease.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Cooper G, Kang S, Perez-Rosello T, et al. (2021) Correction to A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. Acs Chemical Biology |
Cooper G, Kang S, Perez-Rosello T, et al. (2020) A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. Acs Chemical Biology |
Cooper G, Lasser-Katz E, Simchovitz A, et al. (2015) Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus. Journal of Neurophysiology. 114: 1513-20 |
Xu W, Hong SJ, Zeitchek M, et al. (2015) Hydration status regulates sodium flux and inflammatory pathways through epithelial sodium channel (ENaC) in the skin. The Journal of Investigative Dermatology. 135: 796-806 |
Kang S, Cooper G, Dunne SF, et al. (2013) Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorganic & Medicinal Chemistry. 21: 4365-73 |
Kang S, Cooper G, Dunne SF, et al. (2013) Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. Journal of Medicinal Chemistry. 56: 4786-97 |
Kang S, Cooper G, Dunne SF, et al. (2012) CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nature Communications. 3: 1146 |